Tag: Xarleto
Six Additional Weeks of Rivaroxaban Reduces Recurrent VTE
Risk for recurrent venous thromboembolism reduced for patients with isolated distal DVT receiving six additional weeks of rivaroxaban
Rivaroxaban Improves Clinical Outcomes After COVID-19 Hospitalization
Risk for thrombotic events reduced after 35 days of rivaroxaban compared with no extended thromboprophylaxis
Rivaroxaban Cuts Recurrent Blood Clots in Obese Patients
Patients on rivaroxaban also have lower health care resource utilization than those on warfarin
$775 Million Settlement Reached in Xarelto Lawsuits
Patients claim companies failed to warn about the risk for potentially fatal bleeding episodes
Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients
Primary end point occurred in lower percentage of patients in 180-day period; difference not significant
ASH: Rivaroxaban Prevents Blood Clots in At-Risk Cancer Patients
Risk for patients in rivaroxaban group reduced during the on-treatment period
No Clear Benefit for Rivaroxaban After Hospital Discharge
Incidence of major bleeding low with rivaroxaban, but clot risk not lower
Rivaroxaban Linked to Low VTE Recurrence in Active Cancer
Lower rate of VTE recurrence, but higher clinically relevant non-major bleeding versus dalteparin
Aspirin, Rivaroxaban Similar After Total Hip, Knee Arthroplasty
Extended prophylaxis with aspirin no different from rivaroxaban for preventing venous thromboembolism
Rivaroxaban Plus Aspirin Superior for Stable Atherosclerotic Disease
Primary outcome for fewer patients receiving rivaroxaban plus aspirin, but more major bleeding
